Health Condition 1: H912- Sudden idiopathic hearing loss
Conditions
Interventions
Intervention1: Intratympanic Methylprednisolone injection: 0.4 ml inj methylprednisolone (40mg/ml) on alternate days (3 doses)
Control Intervention1: Intratympanic Dexamethasone injection: 0.4 ml inj
Sponsors
Dr Kanika
Eligibility
Inclusion criteria
Inclusion criteria: 1.Individuals aged 18 years or older with sudden sensorineural hearing loss as determined by history & confirmed by audiometry. 2.Patients presenting within 2 weeks of onset of hearing loss.
Exclusion criteria
Exclusion criteria: 1.Patients who do not consent to participate in the study. 2.Patients with middle ear tumours and diseases. 3.Patients with viral infections. 4.Patients with hearing loss of more than 2 weeks duration. 5.Patients who have previously been treated for the same complaint. 6.Patients on ototoxic medication. 7.Patients with traumatic middle ear conditions. 8.Patients with organic disorders such as Type 2 Diabetes Mellitus (T2DM), Chronic Renal Failure (CRF), tuberculosis, peptic ulcers, and glaucoma.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To assess the therapeutic effectiveness of a intratympanic dexamethasone as compared to intratympanic methylprednisolone To evaluate the frequency specific improvement in both group of patients on steroid therapiesTimepoint: To evaluate hearing by PTA at 2, 4 and 8 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| To evaluate the side effects of both drugs in respective groups of patients.Timepoint: To evaluate side effects | — |
Countries
India
Contacts
Public ContactDr Sandeep Bansal
Government Multi Specialty Hospital
Outcome results
None listed